Author: Derek Bagley
Positive Topline Results Announced in Type 1 Diabetes Clinical Trial
A clinical trial investigating a possible novel treatment of early-onset type 1 diabetes last month met the primary endpoint assessing the safety and tolerability of a new class of microbe-based therapeutic agents. Precigen ActoBio is evaluating this therapy — AG019 ActoBiotics — as a monotherapy and in combination with teplizumab. AG019 is formulated as an...
Artificial Pancreas Can Prevent Dangerously Low Blood Sugar in People with Type 1 Diabetes
New system reduces the risk of exercise-related hypoglycemia A new artificial pancreas system can prevent hypoglycemia—episodes of dangerously low blood sugar—during and after heavy exercise in people with type 1 diabetes, according to a small study published in The Journal of Clinical Endocrinology & Metabolism. Despite advances in treatment, blood sugar control in type 1 diabetes remains challenging. The artificial pancreas has the potential to...
Singer/songwriter Crystal Bowersox kicks off the educational initiative by encouraging people to educate their support network and develop a plan for low blood sugar and very low blood sugar emergencies Eli Lilly and Company launched a new initiative earlier this summer to raise awareness about being prepared for these unpredictable conditions. With Know Before the...
Veiled Threats: New Findings Show More Links Between EDCs and Cardiovascular Health
Bone Health Experts Issue Osteoporosis Treatment Guidance During COVID-19
As the COVID-19 pandemic became more serious, the Endocrine Society joined a coalition of bone health organizations that united to issue new osteoporosis treatment guidelines. Aside from addressing the challenges social distancing has placed on treating these patients, the coalition has also focused on the administration of osteoporosis medications including denosumab, teriparatide, abaloparatide, romosozumab, and...